National Institute of Cardiology, Warsaw, Poland.
Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Banacha 1b St, 02-097, Warsaw, Poland.
Health Qual Life Outcomes. 2021 May 5;19(1):138. doi: 10.1186/s12955-021-01780-2.
This study aimed to assess the validity of the EQ-5D-5L in respondents with self-reported diabetes coming from a representative general population survey.
2974 respondents from the general adult population of Poland, chosen with multi-stage random sampling, were surveyed with HRQoL instruments (EQ-5D-5L, EQ VAS, SF-12, EQ-5D-3L) and a screening question about diabetes. To obtain EQ-5D index values, we used country-specific Polish value sets. We compared the instruments in terms of the ceiling effect, discriminatory power and frequency of individual health states. We evaluated construct validity in terms of known-groups validity and convergent validity of EQ-5D-5L dimensions and index values with other HRQoL measures.
In respondents with diabetes (n = 247), the percentage reporting 'no problems' with EQ-5D-3L was reduced by 34.5% with the use of EQ-5D-5L (from 14.2% to 9.3%, respectively). A significant improvement in informativity was noticed in mobility and pain/discomfort dimensions (a relative increase of 23.1% and 22.7%, respectively). Known-groups construct validity analysis confirmed prior hypotheses-index scores were higher in the following groups: younger respondents, males, those taking no medication or oral antidiabetic drugs, and respondents with higher levels of education. The convergence between related EQ-5D-5L and EQ-5D-3L or SF-6D dimensions was stronger than between unrelated dimensions. The Bland-Altman analysis showed a mean difference between EQ-5D-5L and EQ-5D-3L, SF-6D, EQ VAS/100 index scores of 0.047, 0.165 and 0.231 respectively.
Our results support the validity of the EQ-5D-5L descriptive system and EQ-5D-5L index, based on the directly measured value set in respondents with self-reported diabetes coming from the general population.
本研究旨在评估在来自代表性一般人群调查的自我报告糖尿病患者中,EQ-5D-5L 的有效性。
来自波兰一般成年人群的 2974 名受访者通过多阶段随机抽样进行调查,使用 HRQoL 工具(EQ-5D-5L、EQ VAS、SF-12、EQ-5D-3L)和关于糖尿病的筛选问题进行调查。为了获得 EQ-5D 指数值,我们使用了特定于国家的波兰值集。我们比较了这些工具在天花板效应、辨别力和个体健康状况的频率方面的表现。我们根据已知群体的有效性和 EQ-5D-5L 维度和指数值与其他 HRQoL 措施的收敛有效性来评估构效关系的有效性。
在患有糖尿病的受访者(n=247)中,使用 EQ-5D-5L 后,EQ-5D-3L 报告“无问题”的比例降低了 34.5%(分别从 14.2%降至 9.3%)。在移动性和疼痛/不适维度上,信息性得到了显著提高(分别增加了 23.1%和 22.7%)。已知群体构效关系有效性分析证实了先前的假设——指数得分在以下群体中更高:年轻的受访者、男性、未服用药物或口服抗糖尿病药物的受访者以及教育水平较高的受访者。相关的 EQ-5D-5L 和 EQ-5D-3L 或 SF-6D 维度之间的收敛性强于不相关的维度。Bland-Altman 分析显示,EQ-5D-5L 与 EQ-5D-3L、SF-6D、EQ VAS/100 指数得分之间的平均差异分别为 0.047、0.165 和 0.231。
我们的结果支持基于来自一般人群的自我报告糖尿病患者直接测量值集的 EQ-5D-5L 描述性系统和 EQ-5D-5L 指数的有效性。